Kliničko-epidemiološka studija Devikove bolesti u Centralnoj Srbiji
Clinical and epidemiological study of Devicʼs disease in Central Serbia
Author
Martinović, VanjaMentor
Drulović, Jelena
Committee members
Pekmezović, Tatjana
Sokić, Dragoslav

Mesaroš, Šarlota

Dinčić, Evica

Metadata
Show full item recordAbstract
Neuromijelitis optika spektar bolesti (NMOSB), odnosno Devikova bolest, je akvaporin-4
autoantitelom-posredovano demijelinizaciono oboljenje centralnog nervnog sistema, koje dovodi do
teškog stepena neurološke onesposobljenosti, vezane najčešće za vizuelni i motorni sistem, ali i do
značajnog letaliteta.
Ciljevi: Analiza demografskih, kliničkih i parakliničkih karakteristika bolesnika sa NMOSB u Centralnoj
Srbiji i procena njihovog uticaja na dugotrajni ishod bolesti. Osim toga, procenjivana je prevalencija
NMOSB u Centralnoj Srbiji.
Bolesnici i metode: U istraživanje uticaja različitih demografskih, kliničkih i parakliničkih karakteristika
na dugotrajni ishod bolesti je uključeno 74 bolesnika koji ispunjavaju nove kriterijume iz 2015. godine
za NMOSB iz hospitalnog registra obolelih Klinike za neurologiju Kliničkog centra Srbije (KCS). Svi
relevantni podaci prikupljani su iz bolničke dokumentacije. Neurološka onesposobljenost je
kvantifikovana primenom proširene skale stepena neurološ...ke onesposobljenosti (engl. Expanded
disability status scale, EDSS) i Optikospinalnom skalom onesposobljenosti (engl. Opticospinal
impairement scale, OSIS), sa vizuelnim i motornim subskorovima. Prevalencija NMOSB je izračunata
primenom standardnih procedura na osnovu podataka iz Populacionog NMOSB registra Centralne
Srbije.
Rezultati: Relapsno remitentni tok bolesti je imalo 82,4% obolelih. Seropozitivnost AQP4-IgG je
ustanovljena kod 89.2% obolelih. Četrdeset pet od 74 bolesnika su lečeni imunosupresivnom terapijom
(40 – azatioprin, 3 – mikofenolat mofetil, 1 - ciklofosfamid, 1 - mitoksantron, i 2 - rituksimab). Srednje
vreme od početka bolesti do dostizanja EDSS skora 4.0 bilo je 6.5 godina, do EDSS 6.0 bilo je 11.9
godina, i do EDSS 7.0 bilo je 22.0 godine. Faktor za koji je pokazano da povećava rizik za dostizanje
EDSS 4.0, 6.0 i 7.0 je inicijalno veći EDSS. Takođe, kraći prvi inter-relapsni interval je povećavao rizik
za dostizanje EDSS 4.0 i 6.0, a duže vreme od početka bolesti do uvođenja terapije održavanja, rizik za
dostizanje EDSS 7.0. Veći stepen onesposobljenosti koji se odnosi na vidnu funkciju na početku bolesti
bio je prediktor bržeg dostizanja OSIS VA = 6 i VA = 8 (engl. Visual acuity, VA). Teška vidna
onesposobljenost (OSIS VA 6) je ranije dostignuta, ukoliko je bolest počela sa optičkim neuritisom
(medijana,10,0 godina) ili optikospinalnim sindromom (medijana, 11,4 godina), nego posle početka
6
bolesti mijelitisom (medijana, 18,0 godina) (p=0,002). Procenjena prevalencija NMOSB u Centralnoj
Srbiji je 1,03/100 000...
Introduction: Neuromyelitis optica spectrum disorders (NMOSD), or Devic's disease, is an antiaquaporin-
4 autoantibody mediated, demyelinating disease of the central nervous system, which leads to
severe visual and motor disability, and significant case fatality.
Aim: Analysis of demographic, clinical and paraclinical characteristics of patients with NMOSD in the
Central Serbia and assessment of their impact on the long-term outcome of the disease. Assessment of
this disease prevalence, in the same region.
Patients and methods: This study included 74 patients who met the latest 2015 NMOSD diagnostic
criteria, from the hospital registry based at the Neurology clinic, Clinical Center of Serbia (CCS). All
relevant demographic, clinical and paraclinical data were collected from hospital records. Neurological
disability was assessed using the Extended Disability Status Scale (EDSS) score and the Opticospinal
Impairment Scale (OSIS), with visual and motor sub scores. The NMOSD prevalence was... calculated by
standard procedures based on the data from the Central Serbia Registry for NMOSD.
Results: 82.4% of patients had a relapsing-remitting course of the disease. Seropositivity of AQP4-IgG
was found in 89.2% of patients. 45 out of 74 patients were treated with immunosuppressive therapy (40
- azathioprine, 3 - mycophenolate mofetil, 1 - cyclophosphamide, 1 - mitoxantrone, and 2 rituximab).
The median time from disease onset to EDSS score 4.0 was 6.5 years, EDSS 6.0 11.9 years, and EDSS
7.0 22.0 years. Higher baseline EDSS was associated with higher risk of attaining EDSS 4.0, 6.0 and 7.0;
a shorter first inter-attack interval increased the risk for reaching EDSS 4.0 and 6.0; longer time from the
disease onset to the start of treatment administration increased the risk for reaching EDSS 7.0. Worse
visual acuity at the disease onset predicted faster assignment of OSIS VA = 6 and VA = 8. Severe visual
deficit (OSIS VA 6) was reached earlier after optic neuritis (median time,10.0 years) or combined
opticospinal onset (median time, 11.4 years) than after myelitis onset (median time, 18.0 years)
(p=0.002). Estimated prevalence of NMOSD in Central Serbia is 1.03/100 000...
Faculty:
Универзитет у Београду, Медицински факултетDate:
25-06-2021Projects:
- Epidemiological investigation of neurological disorders: global measurement of disease impact (RS-175087)